Results 101 to 110 of about 22,911 (183)
Multicenter clinical evaluation of Etest meropenem-vaborbactam (bioMérieux) for susceptibility testing of Enterobacterales (Enterobacteriaceae) and Pseudomonas aeruginosa [PDF]
Meropenem-vaborbactam (MEV) is a novel carbapenem-beta-lactamase inhibitor combination antibiotic approved by the U.S. Food and Drug Administration (FDA) for treatment of complicated urinary tract infections, including pyelonephritis, in adults.
Davies, Leanne +19 more
core +1 more source
Background Initial antimicrobial therapy for pneumonia is frequently empirical and resistance to antimicrobial agents represents a great challenge to the treatment of patients hospitalized with pneumonia.
Helio S. Sader +4 more
doaj +1 more source
In Vitro Activity of “Old” and “New” Antimicrobials against the Klebsiella pneumoniae Complex
The Klebsiella pneumoniae complex is a commonly isolated bacteria in human infections. These opportunistic pathogens pose a serious threat to public health due to their potential transmission to the human population.
Alicja Sękowska
doaj +1 more source
Purpose This nine-year (2016–2024) surveillance study aimed to investigate the molecular epidemiology and antimicrobial susceptibility profiles of carbapenem-resistant Enterobacterales (CRE) in a tertiary hospital in Central China, with a focus on ...
Yungang Han +12 more
doaj +1 more source
Dose rationale for the use of meropenem/vaborbactam combination in paediatric patients with Gram-negative bacterial infections [PDF]
Aims: Meropenem/vaborbactam combination is approved in adults by FDA and EMA for complicated urinary tract infections and by EMA also for other Gram-negative infections.
Tout, M +14 more
core +1 more source
Flow cytometry enables rapid evaluation of novel, new and niche antimicrobial agents
The global rise of multidrug-resistant bacteria necessitates the development of new antimicrobials and faster diagnostic tools. Conventional antimicrobial susceptibility testing is slow, relying on culture-based methods that delay effective treatment ...
Emily Salisbury +13 more
doaj +1 more source
Introduction/Objective: Serratia marcescens and Enterobacterales of the Morganellaceae family are associated with infections in different sites and exhibit an expected phenotype of resistance to several antimicrobials, making therapeutic options very ...
Lívia Medeiros +5 more
doaj +1 more source
Vaborbactam (formerly RPX7009) is a new beta-lactamase inhibitor based on a cyclic boronic acid pharmacophore. The spectrum of beta-lactamase inhibition by vaborbactam and the impact of bacterial efflux and permeability on its activity were determined ...
Debora Rubio-Aparicio +6 more
core +1 more source
Outline of Meropenem-Vaborbactam for the Treatment of Carbapenem-Resistant Enterobacteriaceae
Dr. Kush Nimron, Dr. Johncy Nathasha
openaire +1 more source
The Place of Meropenem–Vaborbactam in the Management of Carbapenem-Resistant Gram-Negative Infections [PDF]
openaire +2 more sources

